The Infectious disease diagnostics market size at a global level is anticipated to grow at a 7.9% CAGR from 2024 to 2029. It is estimated that the global market was valued at USD 30.90 billion in 2024 and will be worth USD 45.19 billion by 2029.
Most physicians' growing adoption of infectious disease diagnostics is propelling the market growth. In addition, YOY growth in the number of people suffering from infectious diseases in developed economies propels global infectious disease diagnostics market growth.
It has led vitro diagnostic device manufacturers to invest in emerging economies. These companies are trying to develop and commercialize cost-effective tools for infectious disease diagnosis. Disease diagnostics are used to confirm the disease through a quick, precise test result. Being time-consuming, disease diagnostics are on the rise. In addition, infectious disease epidemics are spreading worldwide, leading to increased demand for diagnostic tests. The incidences of malaria, flu, AIDS and other diseases are again rising, creating a robust market for infectious disease diagnostics.
The increasing need to develop novel and useful diagnostic techniques due to the consistently rising population diagnosed with contagious diseases is accelerating the growth of the infectious disease diagnostics market during the forecast period. Furthermore, the emergence of faster and more reliable diagnostic techniques and equipment integrated with artificial intelligence and machine learning offers growth opportunities for the global infectious disease diagnostics market.
High costs associated with diagnostic kits are majorly hampering the market growth. In addition, issues associated with the distribution channels in developing countries are another major factor that negatively impacts market growth.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2024 |
Forecast Period |
2024 to 2029 |
Segments Analysed |
Product, Application, Technology, Traditional methods, End User & Region. |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape; Analyst Overview of Investment Opportunities |
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
Companies Analysed |
Abbott Laboratories, bioMérieux SA, Hologic, Inc., Danaher Corporation, Becton, Dickinson and Company, Cepheid, Inc., Thermo Fisher Scientific Inc., Roche Diagnostics, Alere Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc. |
Based on application, the Hepatitis B segment is the most lucrative and forecasted to register healthy CAGR during the forecast period due to the high prevalence of the disease and increased adoption of advanced diagnostics methods for Hepatitis B. HIV, tuberculosis, and influenza are overgrowing at a high pace. Therefore, it is expected to contribute significantly to the global infectious diagnostics market during the forecast period.
Based on technology, the DNA Sequencing segment is estimated to account for the most significant share of the global market during the forecast period. Furthermore, it is likely to display growth at a high CAGR during the forecast period due to cost reduction and technological improvements in next-generation sequencing.
Based on end-user, the laboratory segment dominated the IDD market in 2023 and is likely to continue the trend during the forecast period owing to the increasing adoption of automated diagnostics technologies in laboratories such as mass spectrometry and PCR.
On the other hand, the hospital segment is anticipated to register a healthy CAGR owing to the factors such as reimbursements offered by the governments, accessibility to the patients, availability of advanced diagnostics equipment in the hospitals, and high flow of patients in hospitals.
Geographically, the North American infectious disease diagnostics market held the largest share of the global IDD market, followed by Europe in 2023 Both regions are projected to witness single-digit growth rates during the coming years. The North American market growth is due to the growing occurrence of contagious diseases and the easy availability of technology instruments. The United States secures the highest demand in the region. In 2014, more than 110,000 deaths occurred due to infectious diseases. Increased incidence of dreadful ailments and the rising need to develop new drugs propel the market's growth rate. For instance, 30 million people in the U.S. alone suffer 7,000 varieties of rare diseases. The Canadian infectious diseases diagnostics market is the fastest growing in North America due to the high awareness levels of practitioners and patients and sophisticated healthcare infrastructure uplifting the market growth.
The European infectious diseases diagnostics market was the second largest globally in 2023 and is predicted to showcase a healthy CAGR during the forecast period. The high adoption of premium diagnostic techniques maintains the market share in the region. Germany leads the infectious diseases diagnostics market in the area. The quick increase in the chronic and contagious disease population and advanced technologies escalate market growth. As per the German Diagnostics Industry Association (VDGH), the IVD and reagent market turnover recorded in 2017 amounted to approximately EUR 2-3 billion. The U.K. market witnessed to have rapid growth during the analysis period. The government's measures to develop suitable healthcare infrastructure among the existing economies propel market demand. The Centre for Excellence in Infectious Diseases Research in Liverpool is engaging with companies to promote diagnostics in malaria, TB, HIV, NTDs, and Sepsis.
Be that as it may, the Asia-Pacific infectious disease diagnostics market is projected to register the highest growth rate in the coming years due to the increased pervasiveness of infectious diseases and tremendous investment opportunities due to a growth in healthcare expenditure. The infectious disease diagnostics market in the Asia-Pacific region is to register a quick growth rate during the estimated period. The increasing frequency of contagious diseases and enormous investment opportunities are due to rising healthcare expenditure. The growing requirement for developing new and valuable diagnostics is an increased population diagnosed with infectious diseases. China is leading the IDD market with impressive market growth. The Chinese government's latest initiative is to mandate that all the blood be tested using nucleic acid technologies by the end of 2015. Acquiring advanced molecular procedures, primarily sexually transmitted diseases such as HIV and bacterial infections, accelerates the market growth. Countries like Japan and India have impressive market growth.
The Latin American infectious disease diagnostics market is anticipated to account for a considerable share of the worldwide market during the forecast period.
The infectious disease diagnostics market in the Middle East and Africa is expected to grow at a steady CAGR in the coming years.
Some of the prominent companies dominating the global infectious disease diagnostics market profiled in the report are Abbott Laboratories, bioMérieux SA, Hologic, Inc., Danaher Corporation, Becton, Dickinson and Company, Cepheid, Inc., Thermo Fisher Scientific Inc., Roche Diagnostics, Alere Inc., DiaSorin S.p.A., Quidel Corporation and Bio-Rad Laboratories, Inc.
By Application
By Technology
By Traditional methods
By End User
By Region
Frequently Asked Questions
The global Infectious disease diagnostics market size was worth USD 28.64 bn in 2023.
The Asia-Pacific is estimated to be the fastest-growing regional market worldwide during the forecast period.
Yes, we have studied and included the COVID-19 impact on the global Infectious disease diagnostics market in this report.
Abbott Laboratories, bioMérieux SA, Hologic, Inc., Danaher Corporation, Becton, Dickinson, and Company, Cepheid, Inc.m, Thermo Fisher Scientific Inc., Roche Diagnostics, Alere Inc., DiaSorin S.p.A., Quidel Corporation and Bio-Rad Laboratories, Inc. are some of the notable players in the infectious disease diagnostics market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region